Literature DB >> 26631087

[Treatment of tuberculosis. Current standards].

T Schaberg1.   

Abstract

The treatment of drug-sensitive tuberculosis consists of 2 months of isoniazid, rifampin, pyrazinamide and ethambutol, followed by 4 months of isoniazid and rifampin. These drugs are well tolerated and cure rate are above 95 %. In contrast the treatment of drug-resistent tuberculosis is difficult, mostly due to side effects of the drugs used under these circumstances. Therefore, any treatment of drug-resistant tuberculosis has to be done by experts.

Entities:  

Keywords:  Drug resistance, bacterial; Drug therapy, combination; Isoniazid; Pyrazinamide; Rifampin

Mesh：

Substances：

Year:  2015        PMID： 26631087     DOI： 10.1007/s00108-015-3759-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


  12 in total

Review 1.  Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease.

Authors:  Heather Milburn; Neil Ashman; Peter Davies; Sarah Doffman; Francis Drobniewski; Saye Khoo; Peter Ormerod; Marlies Ostermann; Catherine Snelson
Journal:  Thorax       Date:  2010-06       Impact factor: 9.139

2.  Extensively drug-resistant tuberculosis: back to the future.

Authors:  G B Migliori; G Sotgiu; C Lange; R Centis
Journal:  Eur Respir J       Date:  2010-09       Impact factor: 16.671

3.  Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

Authors:  Andreas H Diacon; Alexander Pym; Martin P Grobusch; Jorge M de los Rios; Eduardo Gotuzzo; Irina Vasilyeva; Vaira Leimane; Koen Andries; Nyasha Bakare; Tine De Marez; Myriam Haxaire-Theeuwes; Nacer Lounis; Paul Meyvisch; Els De Paepe; Rolf P G van Heeswijk; Brian Dannemann
Journal:  N Engl J Med       Date:  2014-08-21       Impact factor: 91.245

4.  [International Standards of Tuberculosis Care (ISTC)--comments from the German point of view].

Authors:  S Castell; T Bauer; R Diel; A Hedrich; K Magdorf; S Rüsch-Gerdes; T Schaberg; R Loddenkemper
Journal:  Pneumologie       Date:  2012-03-13

5.  Rapid molecular detection of tuberculosis and rifampin resistance.

Authors:  Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins
Journal:  N Engl J Med       Date:  2010-09-01       Impact factor: 91.245

Review 6.  Treatment of latent infection with Mycobacterium tuberculosis: update 2010.

Authors:  C C Leung; H L Rieder; C Lange; W W Yew
Journal:  Eur Respir J       Date:  2010-08-06       Impact factor: 16.671

7.  Delamanid for multidrug-resistant pulmonary tuberculosis.

Authors:  Maria Tarcela Gler; Vija Skripconoka; Epifanio Sanchez-Garavito; Heping Xiao; Jose L Cabrera-Rivero; Dante E Vargas-Vasquez; Mengqiu Gao; Mohamed Awad; Seung-Kyu Park; Tae Sun Shim; Gee Young Suh; Manfred Danilovits; Hideo Ogata; Anu Kurve; Joon Chang; Katsuhiro Suzuki; Thelma Tupasi; Won-Jung Koh; Barbara Seaworth; Lawrence J Geiter; Charles D Wells
Journal:  N Engl J Med       Date:  2012-06-07       Impact factor: 91.245

8.  [Recommendations for therapy, chemoprevention and chemoprophylaxis of tuberculosis in adults and children. German Central Committee against Tuberculosis (DZK), German Respiratory Society (DGP)].

Authors:  T Schaberg; T Bauer; S Castell; K Dalhoff; A Detjen; R Diel; U Greinert; B Hauer; C Lange; K Magdorf; R Loddenkemper
Journal:  Pneumologie       Date:  2012-02-10

9.  A four-month gatifloxacin-containing regimen for treating tuberculosis.

Authors:  Corinne S Merle; Katherine Fielding; Omou Bah Sow; Martin Gninafon; Mame B Lo; Thuli Mthiyane; Joseph Odhiambo; Evans Amukoye; Boubacar Bah; Ferdinand Kassa; Alimatou N'Diaye; Roxana Rustomjee; Bouke C de Jong; John Horton; Christian Perronne; Charalambos Sismanidis; Olivier Lapujade; Piero L Olliaro; Christian Lienhardt
Journal:  N Engl J Med       Date:  2014-10-23       Impact factor: 91.245

10.  Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.

Authors:  Stephen H Gillespie; Angela M Crook; Timothy D McHugh; Carl M Mendel; Sarah K Meredith; Stephen R Murray; Frances Pappas; Patrick P J Phillips; Andrew J Nunn
Journal:  N Engl J Med       Date:  2014-09-07       Impact factor: 91.245
View more
  1 in total

1.  Bengamides display potent activity against drug-resistant Mycobacterium tuberculosis.

Authors:  Diana H Quan; Gayathri Nagalingam; Ian Luck; Nicholas Proschogo; Vijaykumar Pillalamarri; Anthony Addlagatta; Elena Martinez; Vitali Sintchenko; Peter J Rutledge; James A Triccas
Journal:  Sci Rep       Date:  2019-10-07       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.